Dr. Hiddemann on Updated Results of Immunochemotherapy Study in Follicular Lymphoma

Wolfgang Hiddemann, MD, PhD
Published: Friday, Jun 23, 2017



Wolfgang Hiddemann, MD, PhD, director of the Department of Hematology and Oncology, University of Munich, discusses the updated results of an immunochemotherapy study in follicular lymphoma.

Updated results of this international trial comparing obinutuzumab (Gazyva) and rituximab (Rituxan) in patients with previously untreated patients with follicular lymphoma were presented at the 2017 European Hematology Association Congress.

These updates confirmed that the obinutuzumab combination had significantly higher progression-free survival compared with rituximab. The different chemotherapy backbones were also discussed in further detail, says Hiddemann.
 


Wolfgang Hiddemann, MD, PhD, director of the Department of Hematology and Oncology, University of Munich, discusses the updated results of an immunochemotherapy study in follicular lymphoma.

Updated results of this international trial comparing obinutuzumab (Gazyva) and rituximab (Rituxan) in patients with previously untreated patients with follicular lymphoma were presented at the 2017 European Hematology Association Congress.

These updates confirmed that the obinutuzumab combination had significantly higher progression-free survival compared with rituximab. The different chemotherapy backbones were also discussed in further detail, says Hiddemann.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x